Skip to contentI
Insight Molecular Diagnostics Inc.
I
IMDXInsight Molecular Diagnostics Inc. Q2 2021 · 10-Q
Revenue$2.03M$2.03M+1,319.6% vs Q2 2020 Net Income-$10.49M-$10.49MN/M vs Q2 2020 EPS Diluted$0.12$0.12−14.3% vs Q2 2020 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Insight Molecular Diagnostics Inc. · CIK 1642380 · Engraved from SEC EDGAR
Operating Cash Flowderived-$8,058,000N/M Free Cash Flowderived-$8,668,000N/M Margins · derivedGross margin-19.4%+135.8 pt vs Q2 2020
Operating margin-668.4%+5463.1 pt vs Q2 2020
Net margin-516.9%+5852.3 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 11, 2021 · 42 d after period end